Sunshine Lake Pharma
Privately held: no public share price · China
Assets
(5 total)
5Total Assets
0Approved
1Phase 3 / Filed
4Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | FLT3Small molecule | Acute Myeloid Leukemia | |
| Phase 2/3 | Serotonin transporter/5-HT receptorSmall molecule | Major Depressive Disorder | |
| Phase 1 | HIF prolyl hydroxylase domain (PHD1/2/3)Small molecule | Chronic Kidney Disease | |
| Phase 1 | — | Chronic Hepatitis B | |
OlorigliflozinNo recent activity | Phase 1 | SGLT2Small molecule | Type 2 Diabetes |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.